Foresee Pharmaceuticals announced a consolidated revenue of approximately 49.87 million yuan in April, a monthly growth of 17%, a significant increase of 39,165% compared to the same period last year. Foresee's cumulative consolidated revenue for the first four months is approximately 150 million yuan, a significant increase of 439% compared to the same period last year. The company stated that the consolidated revenue for April includes sales income of 41.19 million yuan for supplying the CAMCEVI six-month dosage form to U.S. distributors and a sales profit of 8.68 million yuan for the CAMCEVI six-month dosage form in the U.S. market.
Foresee pointed out that in April, the CAMCEVI six-month dosage form sold 1,779 units in the U.S. terminal market, a decrease of 15% compared to the previous month's 2,089 units due to changes in monthly sales customer combinations, but still a significant increase of 82% compared to the same period last year. Looking ahead, the trend of increasing market share remains unchanged.
According to the licensing agreement signed between Foresee and its U.S. market partner, each CAMCEVI unit's revenue contribution to Foresee includes sales income generated from supplying to the licensing partner and the sales profit that Foresee can enjoy after the licensing partner sells CAMCEVI in the terminal market.
Foresee expects to submit an application for U.S. drug approval for the CAMCEVI three-month dosage form to the U.S. FDA in the second half of this year, with sales scheduled to begin in 2025. Accord Healthcare, Foresee's European licensing partner, plans to launch the CAMCEVI six-month dosage form in Spain in the second half of this year. Foresee's Chinese licensing partner, Changchun GeneScience Pharmaceuticals Co., Ltd., is expected to submit an application for Chinese drug approval for the CAMCEVI six-month dosage form in the second half of this year. In addition, Phase III clinical trials of CAMCEVI for pediatric central precocious puberty and premenopausal breast cancer are actively ongoing.
Foresee pointed out that with the continued advancement of CAMCEVI in new dosage forms, new markets, and new indications, the company's medium- to long-term revenue is expected to accumulate and multiply upward, with growth anticipated.
Resource (Mandarin):
